Rare COVID Vaccine Clotting Linked to Adenoviral Protein - Summary - MDSpire
From the Journals

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 12, 2026

  • 3 min

Share

Researchers have identified the immune response responsible for vaccine-induced immune thrombocytopenia and thrombosis (VITT), a rare clotting disorder linked to adenovirus-based COVID-19 vaccines. The immune system misidentifies platelet factor 4 (PF4), crucial for clotting, as a target, triggered by adenoviral vector proteins. Utilizing advanced techniques like mass spectrometry, the study traced a genetic pattern common among affected patients, revealing how this immune response may be modified in future vaccine designs to mitigate risks without sacrificing efficacy.

Original Source(s)

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

  • May 12, 2026

Related Content

Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...